Vendelsö, Sweden

Charlotte Admyre

USPTO Granted Patents = 8 

 

 

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 4(Granted Patents)


Location History:

  • Vendelso, SE (2017)
  • Vendelsö, SE (2015 - 2018)
  • Stockholm, SE (2014 - 2023)

Company Filing History:


Years Active: 2014-2023

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Charlotte Admyre: Innovator in Therapeutic Oligonucleotides

Introduction

Charlotte Admyre is a prominent inventor based in Vendelsö, Sweden. She has made significant contributions to the field of therapeutic oligonucleotides, holding a total of eight patents. Her work focuses on innovative treatments for inflammatory bowel disease, showcasing her dedication to advancing medical science.

Latest Patents

Among her latest patents, one notable invention provides an oligonucleotide comprising the sequence 5'-GGAACAGTTCGTCCATGGC-3′ (SEQ ID NO:2) for use in the treatment of inflammatory bowel disease in human subjects. This invention details a regimen where individual doses ranging from 100 mg to 350 mg of the oligonucleotide are administered on at least four separate occasions, with each occasion spaced a week apart. Another significant patent involves Cobitolimod, which also utilizes the same oligonucleotide sequence for treating inflammatory bowel disease, with doses of 150 mg to 350 mg administered on at least two occasions, three weeks apart.

Career Highlights

Charlotte Admyre is currently associated with Index Pharmaceuticals AB, where she continues to develop her groundbreaking work in the field of oligonucleotide therapies. Her innovative approach has positioned her as a key figure in the pharmaceutical industry, particularly in the treatment of gastrointestinal diseases.

Collaborations

Charlotte collaborates with talented professionals in her field, including Arezou Zargari and Oliver Von Stein. Their combined expertise contributes to the advancement of therapeutic solutions and enhances the research environment at Index Pharmaceuticals AB.

Conclusion

Charlotte Admyre's contributions to the field of therapeutic oligonucleotides are noteworthy, particularly her innovative approaches to treating inflammatory bowel disease. Her work exemplifies the impact of dedicated inventors in advancing medical treatments and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…